Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 57

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 1
Chunk 57
---
000  
     14,915,000  
     70,054,000  
     41,228,000  
     28,826,000 
  
    ImprimisRx revenue, net 
     21,468,000  
     21,580,000  
     (112,000) 
     41,519,000  
     42,298,000  
     (779,000)

    Total revenues, net 
    $63,742,000  
    $48,939,000  
    $14,803,000  
    $111,573,000  
    $83,526,000  
    $28,047,000 

The
increase in revenues between periods was related to an increase in sales of our branded ophthalmology products, primarily due to the
increase of units sold of IHEEZO and VEVYE during the three and six months ended June 30, 2025 compared to the prior year periods.

Cost
of Sales, Gross Profit and Gross Margin

Our
cost of sales includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients,
personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements depreciation,
the write-off of obsolete inventory, amortization of acquired product NDAs, and other related expenses.

Branded

    Three Months Ended June 30,  
    Six Months Ended June 30, 

    2025  
    2024  
    Variance  
    2025  
    2024  
    Variance 
  
    Cost of Sales 
    $8,734,000  
    $5,559,000  
    $3,175,000  
    $16,915,000  
    $9,237,000  
    $7,678,000 
  
    Gross profit 
    $33,540,000  
    $21,800,000  
    $11,740,000  
    $53,139,000  
    $31,991,000  
    $21,148,000 
  
    Gross margin 
     79.3% 
     79.7% 
     -0.3% 
     75.9% 
     77.6% 
     -